Xenomics, a developer of next-generation medical DNA technologies, announced
today that a team of company scientists has contributed a chapter about the
Xenomics' proprietary transrenal DNA technology platform in a new edition of
a leading scientific textbook about key advances and topics in the field of
modern molecular diagnostic advancements.
Business
Wire
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
Texas Device Manufacturer, Sterilizer Draws FDA Warning Letter
The process challenge packs used for sterilization did not represent the facility’s routinely sterilized components, the agency said.
SK Life Science’s XCOPRI Approved for New Treatment for Adults With Partial-Onset Seizures
The company is expected to make the drug available in the second quarter of 2020.
FDAnews Device Daily Bulletin
XENOMICS' PROPRIETARY MEDICAL DNA TECHNOLOGY DETAILED IN NEW EDITION OF LEADING TEXTBOOK ON ADVANCED MOLECULAR DIAGNOSTICS
April 20, 2006
